Breast cancer program quality

Quality can and should be measured

Through the accreditation process, quality is measured by compliance with standards. These standards are developed by national experts in breast cancer. They measure how well a program delivers the treatments that are proven to work the best.

Percent of the time our program meets or exceeds the highest national standards

Legacy Cancer Institute is shown in the blue bars on the left. Our performance exceeds our peers in all three quality measures.

Radiation therapy after breast conserving surgery

Legacy: 98.1%; programs nationally: 91.1%

The goal is 100%.

Legacy (blue): 98.1%
Pacific region: 88.9%
Nationwide: 91.1%

Quality measure details: Radiation therapy is administered within one year of diagnosis for women under age 70 receiving breast conserving surgery. 

Note: The chart includes women who were offered, but refused radiation.

Chemotherapy for hormone receptor negative breast cancer

Legacy: 95.2%; accredited programs nationally: 91.5%

The goal is 100%


Legacy (blue): 95.2%
Pacific region: 89.7%
Nationwide: 91.5%

Quality measure details: Combination chemotherapy is considered or administered within 120 days of diagnosis for women under 70 with AJCCT1N0M0, or Stage II or III hormone receptor negative breast cancer.

Hormonal therapy for hormone receptor positive breast cancer

Legacy: 99.4%; accredited programs nationally: 88.1%

The goal is 100%


Legacy (blue): 99.4%
Pacific region: 82.9%
Nationwide: 88.1%

Quality measure details: Tamoxifen or third generation aromatase inhibitor is considered or administered within one year of diagnosis for women with AJCC T1cN0M0, or Stage II or III hormone receptor positive breast cancer.